PleoPharma has secured US Food and Drug Administration (FDA) Fast Track designation for PP-01, its lead asset for the mitigation of cannabis withdrawal syndrome in patients with cannabis use disorder.  "We are pleased that PP-01 has been granted Fast Track designation and are grateful to the FDA for recognising the significance of cannabis withdrawal for […]

To read this content in full, you need to login.

Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!